ReviewM. tuberculosis persistence, latency, and drug tolerance
Introduction
The invention of antimicrobial chemotherapy in the 20th century was a watershed event in the history of medicine. Thanks to the new “magic bullets”, many of the most common and deadly infections that had ravaged the US and Europe for centuries became minor and treatable ailments. The first antimicrobials proved ineffective against tuberculosis (TB), the “Great White Plague” that was responsible for more killing more young adults each year than any other infection. The search for a cure finally culminated, in the mid-1940s, in the discovery of streptomycin by Schatz and Waksman and of para-amino salicylate (PAS) by Lehmann. When the more effective drugs isoniazid (INH) and pyrazinamide (PZA) were introduced in the early 1950s, TB became a treatable disease. As predicted by Ehrlich,2 combination therapy with multiple drugs was widely adopted once it was found that “under the influence of two different medicines the danger of rendering the parasites immune, which naturally would be a very great obstacle in connection with further treatment, is apparently greatly minimized.” In his optimistically entitled book “The Conquest of Tuberculosis”, Waksman went so far as to predict that “the ancient foe of man, known as consumption, the great white plague, tuberculosis, or by whatever other name, is on the way to being reduced to a minor ailment of man. The future appears bright indeed, and the complete eradication of the disease is in sight.”3
Forty years later, and despite half a century of anti-TB chemotherapy, there are still 8–10 million new cases of active TB each year, and nearly 2 billion individuals are believed to harbor latent TB based on tuberculin skin test (TST) surveys.4 Why has this treatable bacterial infection failed to yield to modern medicine? While the full answer to this question is complex, one issue seems clear: the features that enable M. tuberculosis to persist within the tissues of its host have also allowed TB to remain one of the world's great killers into the 21st century. This problem was anticipated by Ehrlich2 in 1913, in an historic address at the dawn of the chemotherapy era: “Now that the liability to, and danger of, disease are to a great extent circumscribed … the efforts of chemotherapeutics are directed as far as possible to fill up the gaps left in this ring, more especially to bring healing to diseases in which the natural powers of the organism are insufficient”. Ninety years later, the ring has not yet been closed in the case of TB, where the “natural powers” of the human immune system are clearly “insufficient” to resolve infection.
Section snippets
Latency, dormancy, and persistence
Three terms, latency, persistence, and dormancy, are commonly used in describing M. tuberculosis and TB pathogenesis. Because these terms have not always been used consistently in the literature, they will be defined here as they will be used in this review, with our apologies to those whose ideas differ. Latency was defined by Amberson5 as “the presence of any tuberculous lesion which fails to produce symptoms of its presence”. Latency can be achieved through either the early restriction of M.
Persistence ex vivo
Long before the discovery of streptomycin and other antimicrobials, M. tuberculosis was known to be an unusually hardy bacterium, both inside and outside the body. In the early 20th century, researchers subjected M. tuberculosis to a barrage of environmental assaults to ascertain which conditions affected the organism's viability and virulence (8 and references therein). M. tuberculosis proved quite adept at withstanding a wide variety of ex vivo insults, including desiccation, nutrient
Latency
Prior to the antibiotic era, TB was considered a lifelong infection: “Once tuberculous, always tuberculous”. This clinical adage was recently given a new twist by a molecular epidemiology study in Denmark, which provided the first compelling molecular evidence for the existence of extraordinarily long periods of latency in untreated humans.10 This study examined the case of a Danish man who first developed TB in 1990. When the IS6110 fingerprint of the M. tuberculosis strain isolated from this
Drug tolerance
If the fate of bacilli in naturally healed lesions continues to be controversial, the status of tubercle bacilli within patients treated with antimicrobials is even less clear. Following the introduction of TB chemotherapy in the late 1940s, surgical resection of tuberculous lesions became increasingly common and provided material for numerous bacteriological studies. Several reports published in the mid-1950s showed that large numbers of acid-fast bacilli could be observed by microscopy in
Modeling persistence in vitro
The simplest model of M. tuberculosis persistence is the stationary phase culture. The kinetics of replication of M. tuberculosis in the lungs of mice are reminiscent of the organism's replication kinetics in culture: an initial period of exponential growth is followed by an extended period during which the number of viable bacilli remains stable. Admittedly, the forces that bring about the cessation of growth in vitro (nutrient exhaustion) are not equivalent to those in vivo (acquired
Modeling persistence in animals
The phenomenon of latency has been difficult to reproduce in a tractable small animal model. Apart from non-human primates,57 which are prohibitively expensive and impractical for general use, rabbits provide the closest facsimile of human tuberculosis in terms of tissue pathology and disease progression. Half a century ago, Lurie bred resistant and susceptible strains of rabbits, and demonstrated that the differential outcome of TB infections in these strains was determined by early events
Recent progress
During the past decade, the development of molecular-genetic tools for the analysis of M. tuberculosis has significantly advanced our ability to study the in vivo biology of M. tuberculosis.83 Genetic and gene expression-based studies have led to the identification of genes that appear to be involved in the adaptation of M. tuberculosis to life in the lungs. The mouse continues to be the most frequently used model for studies of M. tuberculosis pathogenesis, although there has been a renewal of
What next?
During the past decade, there has been a resurgence of interest in the phenomenon of M. tuberculosis persistence. In the United States, this has been due in part to the recognition that the demographics of TB are shifting.95 In 1990, three-quarters of all TB cases in the United States were among the US-born; a decade later, the numbers of cases among the US-born and foreign-born were roughly equal. Most significantly, from 1990 to 2000, there was a marked fall in the absolute number of TB cases
References (107)
- et al.
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after curea cohort study in South African mineworkers
Lancet
(2001) - et al.
Pathogenesis of tuberculosispathway to apical localization
Tuberc Lung Dis
(1994) - et al.
Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection
Lancet
(2000) - et al.
Protein synthesis is shut down in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock
FEMS Microbiol Lett
(1998) - et al.
Mechanisms of latency in Mycobacterium tuberculosis
Trends Microbiol
(1998) - et al.
Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice
Immunity
(1995) The immunopathogenesis of tuberculosisa new working hypothesis
Trends Microbiol
(1998)The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy
Tubercle
(1987)- et al.
Microbial pathogenesis of Mycobacterium tuberculosisdawn of a discipline
Cell
(2001) - et al.
A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis
Mol Cell
(2000)
Regulation of virulence genes in Mycobacterium tuberculosis
Int J Med Microbiol
Specific immune-based diagnosis of tuberculosis
Lancet
Inapparent infectionrelation of latent and dormant infection to microbial persistence
Pub Health Rep
Address in pathology on chemotherapeuticsscientific principles, methods, and results
Lancet
The conquest of tuberculosis
Global burden of tuberculosisestimated incidence, prevalence, and mortality by country
JAMA
The significance of latent forms of tuberculosis
N Engl J Med
The primary complex in human tuberculosis and its significance
Am Rev Tuberc
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence
Infect Immun
The viability and virulence of old cultures of tubercle bacillistudies on twelve-year broth cultures maintained at incubator temperature
Am Rev Tuberc
Nonreplicating persistence of Mycobacterium tuberculosis
Annu Rev Microbiol
Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection
J Infect Dis
Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment
N Engl J Med
Epidemiology of tuberculosis
The pathogenesis of tuberculosis
Immunopathogenesis of pulmonary tuberculosis
Hosp Pract (Off Ed)
Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions
Arch Pathol
The occurrence of virulent tubercle bacilli in presumably non-tuberculous lung tissue
Am J Pathol
The residual infectivity of the primary complex of tuberculosis
Am J Pathol
Tuberculous infection in people dying of causes other than tuberculosis
Am Rev Tuberc
A study of the tubercle bacillus in resected pulmonary lesions
Am Rev Tuberc
A bacteriologic study of resected tuberculous lesions
Am Rev Tuberc
The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans
Am Rev Tuberc
The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis
Am J Med Sci
The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection
Am J Med Sci
The bacteriology of resected tuberculous pulmonary lesions. I. The effect of interval between reversal of infectiousness and subsequent surgery
Am Rev Tuberc Pulm Dis
Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculosis infection to the latent state by the administration of tuberculosis and a companion drug
J Exp Med
Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug susceptible bacilli in the tissues despite prolonged antimicrobial therapy
J Exp Med
Microbial persistence II. Characteristics of the sterile state of tubercle bacilli
J Exp Med
Microbial persistence I. The capacity of tubercle bacilli to survive sterilization in mouse tissues
J Exp Med
Distribution and excretion of radioactive isoniazid in tuberculosis patients
JAMA
Studies on the gaseous content of tuberculous cavities
Am Rev Respir Dis
The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells
Am Rev Tuberc
Observations on the mechanism of action of penicillin
Proc Soc Exp Biol Med
Multiple antibiotic resistance in a bacterium with suppressed autolytic system
Nature
Phenotypic tolerancethe search for beta-lactam antibiotics that kill nongrowing bacteria
Rev Infect Dis
Drug tolerance in Mycobacterium tuberculosis
Antimicrob Agents Chemother
Mycobacterial persistenceadaptation to a changing environment
Trends Microbiol
The role of Rel Mtb-mediated adaption to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice
Proc Natl Acad Sci USA
Cited by (456)
Characteristics of Mycobacterium tuberculosis serine protease Rv1043c in enzymology and pathogenicity in mice
2023, Journal of Integrative AgricultureSAR study of piperidine derivatives as inhibitors of 1,4-dihydroxy-2-naphthoate isoprenyltransferase (MenA) from Mycobacterium tuberculosis
2023, European Journal of Medicinal ChemistryMesenchymal stem cells—role in tuberculosis pathogenesis and persistence
2023, Stem Cells: an Alternative Therapy for COVID-19 and Cytokine StormBigger problems from smaller colonies: emergence of antibiotic-tolerant small colony variants of Mycobacterium avium complex in MAC-pulmonary disease patients
2024, Annals of Clinical Microbiology and Antimicrobials